Connection

STEVEN SCHERER to Genotype

This is a "connection" page, showing publications STEVEN SCHERER has written about Genotype.
Connection Strength

0.605
  1. Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun. 2018 02 26; 9(1):828.
    View in: PubMed
    Score: 0.096
  2. Assessing the impact of FoxP3 and Vav1 gene polymorphisms on kidney allograft survival. HLA. 2017 08; 90(2):102-105.
    View in: PubMed
    Score: 0.091
  3. Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic. Pharmacogenomics. 2024; 25(16-18):637-645.
    View in: PubMed
    Score: 0.039
  4. An efficient genotyper and star-allele caller for pharmacogenomics. Genome Res. 2023 01; 33(1):61-70.
    View in: PubMed
    Score: 0.034
  5. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022 05; 24(5):1062-1072.
    View in: PubMed
    Score: 0.032
  6. Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes. Pharmacogenet Genomics. 2022 06 01; 32(4):159-172.
    View in: PubMed
    Score: 0.032
  7. CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project. J Mol Diagn. 2022 04; 24(4):337-350.
    View in: PubMed
    Score: 0.032
  8. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing? J Mol Diagn. 2022 03; 24(3):253-261.
    View in: PubMed
    Score: 0.032
  9. Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. Nicotine Tob Res. 2020 May 26; 22(6):910-918.
    View in: PubMed
    Score: 0.028
  10. Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. J Neuromuscul Dis. 2019; 6(2):201-211.
    View in: PubMed
    Score: 0.026
  11. A novel MFN2 mutation causes variable clinical severity in a multi-generational CMT2 family. Neuromuscul Disord. 2019 02; 29(2):134-137.
    View in: PubMed
    Score: 0.025
  12. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.022
  13. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain. 2015 Nov; 138(Pt 11):3180-92.
    View in: PubMed
    Score: 0.020
  14. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain. 2014 Jan; 137(Pt 1):44-56.
    View in: PubMed
    Score: 0.018
  15. No impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation. Am J Transplant. 2013 Apr; 13(4):1063-1068.
    View in: PubMed
    Score: 0.017
  16. A genetic map of Xenopus tropicalis. Dev Biol. 2011 Jun 01; 354(1):1-8.
    View in: PubMed
    Score: 0.015
  17. Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A. 2010 Dec 07; 107(49):21104-9.
    View in: PubMed
    Score: 0.015
  18. Reassessing the impact of donor HLA-C genotype on long-term liver transplant survival. Am J Transplant. 2009 Jul; 9(7):1674-8.
    View in: PubMed
    Score: 0.013
  19. T118M PMP22 mutation causes partial loss of function and HNPP-like neuropathy. Ann Neurol. 2006 Feb; 59(2):358-64.
    View in: PubMed
    Score: 0.010
  20. Mapping a locus for familial thoracic aortic aneurysms and dissections (TAAD2) to 3p24-25. Circulation. 2003 Jul 01; 107(25):3184-90.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.